Drug Profile
ATx09 002
Alternative Names: ATx09-002; PSN-357; PSN357ABLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Prosidion
- Developer Aestus Therapeutics; Prosidion
- Class Antihyperglycaemics
- Mechanism of Action Glycogen phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Back pain; Neuropathic pain; Type 2 diabetes mellitus
Most Recent Events
- 23 Feb 2023 Discontinued - Phase-I for Back pain in USA (PO)
- 23 Feb 2023 Discontinued - Preclinical for Neuropathic pain in USA (PO)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Back-pain in USA (PO)